NASDAQ:CAPR - Capricor Therapeutics Stock Price, Forecast & News

Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."

Capricor Therapeutics Inc (NASDAQ:CAPR) announced its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.70) by $0.27. The biotechnology company had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.22 million. Capricor Therapeutics had a negative return on equity of 264.61% and a negative net margin of 660.66%. View Capricor Therapeutics' Earnings History.

Capricor Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Capricor Therapeutics.

2 analysts have issued 1-year price targets for Capricor Therapeutics' shares. Their forecasts range from $9.00 to $9.00. On average, they anticipate Capricor Therapeutics' share price to reach $9.00 in the next twelve months. This suggests a possible upside of 547.5% from the stock's current price. View Analyst Price Targets for Capricor Therapeutics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Capricor Therapeutics.

News headlines about CAPR stock have trended very positive recently, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Capricor Therapeutics earned a news impact score of 3.1 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Capricor Therapeutics.

Capricor Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totalling 48,100 shares, an increase of 75.5% from the January 15th total of 27,400 shares. Based on an average daily volume of 154,600 shares, the days-to-cover ratio is currently 0.3 days. Currently, 1.5% of the shares of the stock are short sold. View Capricor Therapeutics' Current Options Chain.

Some companies that are related to Capricor Therapeutics include Guardion Health Sciences (GHSI), Aptevo Therapeutics (APVO), Ceapro (CRPOF), Cellectar Biosciences (CLRB), Tocagen (TOCA), OHR Pharmaceutical (OHRP), AEterna Zentaris (AEZS), ProPhase Labs (PRPH), Aileron Therapeutics (ALRN), Dare Bioscience (DARE), OncoSec Medical (ONCS), Spring Bank Pharmaceuticals (SBPH), Bio-Path (BPTH), Adial Pharmaceuticals (ADIL) and Regulus Therapeutics (RGLS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Capricor Therapeutics investors own include Marinus Pharmaceuticals (MRNS), Chesapeake Energy (CHK), Nabriva Therapeutics (NBRV), Agile Therapeutics (AGRX), BIOLINERX LTD/S (BLRX), Actinium Pharmaceuticals (ATNM), Aurinia Pharmaceuticals (AUPH), BioMarin Pharmaceutical (BMRN), Eyepoint Pharmaceuticals (EYPT) and Protalix Biotherapeutics (PLX).

Capricor Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.97%). View Institutional Ownership Trends for Capricor Therapeutics.

CAPR stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Capricor Therapeutics.

Shares of CAPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CAPR stock can currently be purchased for approximately $1.39.

Capricor Therapeutics has a market capitalization of $5.91 million and generates $1.67 million in revenue each year. The biotechnology company earns $-15,190,000.00 in net income (profit) each year or ($5.20) on an earnings per share basis. View Additional Information About Capricor Therapeutics.

The official website for Capricor Therapeutics is http://www.capricor.com/.

Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The biotechnology company can be reached via phone at 310-358-3200 or via email at [email protected]